Thermo Fisher's test to detect pregnancy-related complication gets FDA nod
Reuters
Published May 19, 2023 08:18AM ET
Updated May 19, 2023 02:42PM ET
(Reuters) -The U.S. Food and Drug Administration (FDA) has cleared Thermo Fisher Scientific Inc (NYSE:TMO)'s test, the first of its kind in the country, to detect women with risk of severe preeclampsia, the company said on Friday.
Preeclampsia is a leading cause of mortality in pregnant women globally, where they could experience high blood pressure after 20 weeks of pregnancy and during the postpartum period.
The condition happens in about 1 in 25 pregnancies in the United States, according to the U.S. Centers for Disease Control and Prevention.
The FDA clearance is based on a study that examined data from over 700 pregnant women in 18 U.S. hospitals.
The regulatory nod for the biomarker test will have a significant impact on prognosis and treatment for thousands of women at risk for preeclampsia every year in the U.S, said Alan Sachs, chief medical officer at Thermo Fisher Scientific.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.